China's drug regulator granted ZhuZhou QianJin Pharmaceutical (SHA:600479) and subsidiary Hunan Qianjin Xiangjiang Pharmaceutical drug registration certificates for dienogest tablets, potassium chloride granules, and ailamode tablets.
Dienogest is indicated for endometriosis and could shrink ovarian endometriotic cysts, according to a Wednesday filing with the Shanghai bourse.
Ailamode is indicated for active rheumatoid arthritis, while the potassium chloride granules help prevent and treat hypokalemia, or a lack of potassium in the blood, with or without metabolic alkalosis.